CO5160246A1 - METHOD FOR THE PREVENTION OR REDUCTION OF CARDIOVASCULAR EPISODES ASSOCIATED WITH CORONARY INTERVENTIONS - Google Patents
METHOD FOR THE PREVENTION OR REDUCTION OF CARDIOVASCULAR EPISODES ASSOCIATED WITH CORONARY INTERVENTIONSInfo
- Publication number
- CO5160246A1 CO5160246A1 CO00006605A CO00006605A CO5160246A1 CO 5160246 A1 CO5160246 A1 CO 5160246A1 CO 00006605 A CO00006605 A CO 00006605A CO 00006605 A CO00006605 A CO 00006605A CO 5160246 A1 CO5160246 A1 CO 5160246A1
- Authority
- CO
- Colombia
- Prior art keywords
- prevention
- reduction
- coronary
- approximately
- coronary interventions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Un método para la prevención o la reducción de episodios cardiovasculares asociados con intervenciones coronarias en mamíferos, particularmente en personas, que comprende administrar al sujeto ácido N-(3´,4´-dimetoxicinamoil)antranílico (N-5´) o una sal del mismo aceptable farmacéuticamente en una dosis diaria de aproximadamente 300 mg a aproximadamente 1.100 mg en asociación con la intervención coronaria.1El uso de ácido N-(3´,4´-dimetoxicinamoil)antranílico (N-5´), o una sal del mismo aceptable farmacéuticamente, en la confección de un medicamento para ser usado en la prevención o la reducción de episodios cardiovasculares asociados con intervenciones coronarias en un mamífero, en particular en una persona, cuando se administra en asociación con una intervención coronaria en una dosis diaria de aproximadamente 300 mg a aproximadamente 1.100 mg.2Una composición farmacéutica para ser usada en la prevención o la reducción de episodios cardiovasculares asociados con intervenciones coronarias en un mamífero, en particular en una persona, cuando se administra en asociación con una interverción coronaria en una dosis diaria de aproximadamente 300 mg a aproximadamente 1.100 mg, que comprende ácido N-(3´,4´-dimetoxicinamoil)antranílico (N-5´) o una sal del mismo aceptable farmacéuticamente.A method for the prevention or reduction of cardiovascular events associated with coronary interventions in mammals, particularly in people, which comprises administering to the subject N- (3´, 4´-dimethoxycinnamoyl) anthranilic acid (N-5´) or a salt of the same pharmaceutically acceptable at a daily dose of about 300 mg to about 1,100 mg in association with coronary intervention.1 The use of N- (3´, 4´-dimethoxycinnamoyl) anthranilic acid (N-5´), or a salt thereof pharmaceutically acceptable, in the preparation of a medicament for use in the prevention or reduction of cardiovascular events associated with coronary interventions in a mammal, in particular in a person, when administered in association with a coronary intervention in a daily dose of approximately 300 mg to approximately 1,100 mg. 2 A pharmaceutical composition for use in the prevention or reduction of associated cardiovascular events. os with coronary interventions in a mammal, particularly in a person, when administered in association with a coronary intervention at a daily dose of approximately 300 mg to approximately 1,100 mg, comprising N- (3´, 4´-dimethoxycinnamoil) anthranilic (N-5 ') or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11846399P | 1999-02-03 | 1999-02-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5160246A1 true CO5160246A1 (en) | 2002-05-30 |
Family
ID=22378760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00006605A CO5160246A1 (en) | 1999-02-03 | 2000-02-03 | METHOD FOR THE PREVENTION OR REDUCTION OF CARDIOVASCULAR EPISODES ASSOCIATED WITH CORONARY INTERVENTIONS |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1180027A4 (en) |
| JP (1) | JP2002536326A (en) |
| KR (1) | KR20010101933A (en) |
| CN (1) | CN1338930A (en) |
| AR (1) | AR022475A1 (en) |
| AU (1) | AU2978500A (en) |
| BR (1) | BR0007901A (en) |
| CA (1) | CA2361578A1 (en) |
| CO (1) | CO5160246A1 (en) |
| HU (1) | HUP0200148A3 (en) |
| IL (1) | IL144719A0 (en) |
| MX (1) | MXPA01007833A (en) |
| NO (1) | NO20013789L (en) |
| PL (1) | PL349926A1 (en) |
| TR (1) | TR200102262T2 (en) |
| WO (1) | WO2000045810A1 (en) |
| ZA (1) | ZA200106297B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8097650B2 (en) * | 2005-07-27 | 2012-01-17 | The Trustees Of Columbia University In The City Of New York | Method of treating a condition associated with phosphorylation of TASK-1 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2617407B2 (en) * | 1992-09-14 | 1997-06-04 | キッセイ薬品工業株式会社 | Preventive and therapeutic agent for intimal cell hyperproliferative disease |
| WO1997009301A1 (en) * | 1995-09-07 | 1997-03-13 | Kissei Pharmaceutical Co., Ltd. | 2-acylaminobenzamide derivatives and preventive and remedy for diseases caused by the supermultiplication of vascular intimal cells |
| US6019104A (en) * | 1996-12-30 | 2000-02-01 | Kissei Pharmaceutical Co., Ltd. | Method for the treatment or prevention of restenosis associated with coronary intervention |
-
2000
- 2000-02-02 JP JP2000596930A patent/JP2002536326A/en not_active Withdrawn
- 2000-02-02 TR TR2001/02262T patent/TR200102262T2/en unknown
- 2000-02-02 PL PL00349926A patent/PL349926A1/en not_active Application Discontinuation
- 2000-02-02 EP EP00908440A patent/EP1180027A4/en not_active Withdrawn
- 2000-02-02 AR ARP000100437A patent/AR022475A1/en unknown
- 2000-02-02 CN CN00803386A patent/CN1338930A/en active Pending
- 2000-02-02 KR KR1020017009743A patent/KR20010101933A/en not_active Application Discontinuation
- 2000-02-02 IL IL14471900A patent/IL144719A0/en unknown
- 2000-02-02 WO PCT/US2000/002611 patent/WO2000045810A1/en not_active Application Discontinuation
- 2000-02-02 BR BR0007901-4A patent/BR0007901A/en not_active Application Discontinuation
- 2000-02-02 CA CA002361578A patent/CA2361578A1/en not_active Abandoned
- 2000-02-02 HU HU0200148A patent/HUP0200148A3/en unknown
- 2000-02-02 MX MXPA01007833A patent/MXPA01007833A/en unknown
- 2000-02-02 AU AU29785/00A patent/AU2978500A/en not_active Abandoned
- 2000-02-03 CO CO00006605A patent/CO5160246A1/en unknown
-
2001
- 2001-07-31 ZA ZA200106297A patent/ZA200106297B/en unknown
- 2001-08-02 NO NO20013789A patent/NO20013789L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1338930A (en) | 2002-03-06 |
| ZA200106297B (en) | 2002-07-31 |
| BR0007901A (en) | 2001-10-30 |
| NO20013789D0 (en) | 2001-08-02 |
| EP1180027A1 (en) | 2002-02-20 |
| KR20010101933A (en) | 2001-11-15 |
| MXPA01007833A (en) | 2002-06-21 |
| TR200102262T2 (en) | 2002-02-21 |
| WO2000045810A1 (en) | 2000-08-10 |
| HUP0200148A2 (en) | 2002-05-29 |
| AR022475A1 (en) | 2002-09-04 |
| CA2361578A1 (en) | 2000-08-10 |
| AU2978500A (en) | 2000-08-25 |
| PL349926A1 (en) | 2002-10-21 |
| HUP0200148A3 (en) | 2003-06-30 |
| JP2002536326A (en) | 2002-10-29 |
| EP1180027A4 (en) | 2004-11-17 |
| IL144719A0 (en) | 2002-06-30 |
| NO20013789L (en) | 2001-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1138329B1 (en) | Composition containing 5-Methyl-1-phenyl-2-(1 H)-pyridone for reparation and prevention of fibrotic lesions | |
| CR6458A (en) | VALDECOXIB COMPOSITIONS | |
| CY1105707T1 (en) | COMBINATIONS OF FORMOTEROL AND A TRIOTROP SALT | |
| DE69331409T2 (en) | ORAL 1ALPHA HYDROXYPREVITAMIN D | |
| KR930702022A (en) | Treatment or prevention of type 1 diabetes by oral administration of insulin | |
| ES2188782T3 (en) | PHARMACEUTICAL FORMULATIONS CONTAINING DARIFENACINE. | |
| AR020803A1 (en) | A COMPOSITION THAT INCLUDES FEXOFENADINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINE | |
| WO2002042462A3 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| EA200000468A1 (en) | THERAPEUTIC COMPOSITION FOR THE ADMINISTRATION OF TOLTERODINE WITH CONTROLLED DELIVERY | |
| AR037255A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING OXIBUTININE | |
| BR9916860A (en) | Method of reducing blood cholesterol and / or other blood glycerides in a mammal individual, preparation in the form of a dosage unit, and, set to orally administer the same | |
| AR008392A1 (en) | PROCEDURE USING A GREEN PORPHYRIN TO PREPARE A MEDICINAL PRODUCT TO PREVENT OR INHIBIT ARTERIAL PLATE FORMATION AND PHARMACEUTICAL COMPOSITION OBTAINED BY SUCH PROCEDURE | |
| AR015744A1 (en) | USE OF DEXMEDETOMIDINE FOR SEDATION IN INTENSIVE THERAPY | |
| ATE311928T1 (en) | (-)-PSEUDOEPHEDRINE AS A SYMPATHOMIMETIC DRUG | |
| UY25798A1 (en) | PHARMACEUTICAL COMPOSITION OF MODIFIED RELEASE INCLUDING A THIAZOLIDINADIONIC INSULIN SENSITIZER. | |
| CO5160246A1 (en) | METHOD FOR THE PREVENTION OR REDUCTION OF CARDIOVASCULAR EPISODES ASSOCIATED WITH CORONARY INTERVENTIONS | |
| AR025549A1 (en) | MICOFELONATE MOFETIL IN ASSOCIATION WITH PEG-IFN-ALFA | |
| AR012638A1 (en) | USE OF PREGNAN-3-OL-20-ONAS FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT TO PROVIDE PROGESTATIONAL THERAPY | |
| CO5150206A1 (en) | METHOD FOR THE PREVENTION OR REDUCTION OF CARDIOVASCULAR EPISODES ASSOCIATED WITH CORONARY INTERVENTIONS | |
| AR062894A1 (en) | FORMULATIONS FOR THERAPEUTIC ESTIMULATION HORMONE THERAPEUTIC ADMINISTRATION (THS) | |
| SE8804640L (en) | MEDICINAL COMPREHENSIVE CYCLOLINOPEPTIDE A | |
| KR950700063A (en) | Brofaromine as an agent for treating post-traumatic stress | |
| AU4918900A (en) | Interferon-beta use in the treatment of ewing's family of tumors | |
| ITRM20010695A1 (en) | USE OF PROPIONIL L-CARNITINE OR ITS PHARMACOLOGICALLY ACCEPTABLE SALT FOR THE PREPARATION OF A MEDICATION FOR THE TREATMENT OF | |
| AR003957A1 (en) | PHARMACEUTICAL COMPOSITION TO TREAT A MAMMAL PATIENT SUFFERING FROM A PROGRESSIVE CHRONIC VASCULAR DISEASE (CPVD) |